Grifols
Grifols, officially known as Grifols, S.A., is a global leader in the biopharmaceutical industry, headquartered in Barcelona, Spain (ES). Founded in 1940, the company has established a strong presence in key operational regions, including Europe, North America, and Latin America. Grifols specialises in the development of plasma-derived medicines, diagnostic solutions, and hospital products, with a commitment to improving patient health. The company is renowned for its innovative therapies, particularly in the treatment of rare and chronic diseases, setting it apart in a competitive market. Grifols has achieved significant milestones, including the expansion of its plasma collection network and advancements in immunology. With a robust market position, Grifols continues to be recognised for its contributions to healthcare, making it a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does Grifols's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grifols's score of 78 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grifols's reported carbon emissions
In 2024, Grifols reported total greenhouse gas emissions of approximately 1,231,771,000 kg CO2e, with Scope 1 emissions at about 106,289,000 kg CO2e, Scope 2 emissions (market-based) at approximately 73,876,000 kg CO2e, and Scope 3 emissions reaching about 1,051,606,000 kg CO2e. This represents a significant increase from 2023, where total emissions were about 1,152,027,000 kg CO2e. Grifols has set ambitious climate commitments, aiming for a 55% reduction in greenhouse gas emissions per production unit by 2030, compared to 2018 levels. Additionally, they plan to reduce absolute Scope 1 and 2 emissions by 42% by 2030, using 2022 as the baseline year. For Scope 3 emissions, Grifols targets a 25% reduction within the same timeframe. The company is also committed to achieving net-zero emissions for Scope 1 and 2 by 2050. In the near term, Grifols aims to reduce its Scope 1 emissions to near zero by 2025 and Scope 2 emissions to near zero by the same year. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Grifols's commitment to sustainable practices within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 67,369,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 122,508,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 102,600,000 | 00,000,000 | 00,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grifols is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
